Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.41 |
| ▸ | FAP | Q12884 | 3/20 | 0.41 |
| ▸ | MC4R | P32245 | 4/20 | 0.39 |
| ▸ | MC3R | P41968 | 4/20 | 0.39 |
| ▸ | MC1R | Q01726 | 4/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042026 | 0.93 | DPP4 (0.46) | DPP4 | |
| SCHEMBL4038911 | 0.90 | DPP4 (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4038500 | 0.88 | DPP4 (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4042815 | 0.87 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4044728 | 0.85 | DPP4 (0.40) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL4042325 | 0.85 | DPP4 (0.40) | DPP4 | |
| SCHEMBL4040220 | 0.85 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4046221 | 0.85 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4040449 | 0.85 | DPP4 (0.43) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL6211121 | 0.84 | CTSK (0.43) | MC4RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | DPP4 3448/4885DPP8 947/4885DPP9 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.